Stephanie KY Ma

Dr. Stephanie KY Ma

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
SMStephanie KY Ma
Stephanie KY Ma
KCKwok–Wah Chan
Kwok–Wah Chan
LHLiang Hu
Liang Hu
KLKin Wah Terence Lee
Kin Wah Terence Lee
JWJana Yim–Hung Wo
Jana Yim–Hung Wo
Xin-Yuan GuanXin-Yuan Guan
Xin-Yuan Guan

1 November 2018 in Cell
Verified
Journal Article
Closed access
HHHuili Hu
Huili Hu
HGHelmuth Gehart
Helmuth Gehart
BABenedetta Artegiani
Benedetta Artegiani
CLCarmen Löpez-Iglesias
Carmen Löpez-Iglesias
FDFlorijn Dekkers
Florijn Dekkers
Hans CleversHans Clevers
Hans Clevers

1 December 2018 in Cell Stem Cell
Verified
Journal Article
Closed access
HYHelen H.N. Yan
Helen H.N. Yan
HSHoi Cheong Siu
Hoi Cheong Siu
SLSimon Law
Simon Law
SHSiu Lun Ho
Siu Lun Ho
SYSarah S.K. Yue
Sarah S.K. Yue
SLSum Yee Yee Leung
Sum Yee Yee Leung

1 July 2011 in Cell Stem Cell
Verified
Journal Article
Closed access
KLKin Wah Terence Lee
Kin Wah Terence Lee
ACAntonia Castilho
Antonia Castilho
VCVincent Chi Ho Cheung
Vincent Chi Ho Cheung
KTKwan Ho Tang
Kwan Ho Tang
SMStephanie KY Ma
Stephanie KY Ma
INIrene Oi Lin Ng
Irene Oi Lin Ng

9 September 2021 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
TLTerence Kin-Wah Lee
Terence Kin-Wah Lee
Xin-Yuan GuanXin-Yuan Guan
Xin-Yuan Guan
SMStephanie KY Ma
Stephanie KY Ma

1 July 2008 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
SMStephanie KY Ma
Stephanie KY Ma
KCKwok Wah Chan
Kwok Wah Chan
KLKin Wah Terence Lee
Kin Wah Terence Lee
KTKwan Ho Tang
Kwan Ho Tang
JWJana Yim-Hung Wo
Jana Yim-Hung Wo
Xin-Yuan GuanXin-Yuan Guan
Xin-Yuan Guan
Recent efforts in our study of cancer stem cells (CSC) in hepatocellular carcinoma (HCC) have led to the identification of CD133 as a prominent HCC CSC marker. Findings were based on experiments done on cell lines and xenograft tumors where expression of CD133 was detected at levels as high as 65%. Based on the CSC theory, CSCs are believed to represent only a minority number of the tumor mass. This is indicative that our previously characterized CD133+ HCC CSC population is still heterogeneous, consisting of perhaps subsets of cells with differing tumorigenic potential. We hypothesized that it is possible to further enrich the CSC population by means of additional differentially expressed markers. Using a two-dimensional PAGE approach, we compared protein profiles between CD133+ and CD133− subpopulations isolated from Huh7 and PLC8024 and identified aldehyde dehydrogenase 1A1 as one of the proteins that are preferentially expressed in the CD133+ subfraction. Analysis of the expression of several different ALDH isoforms and ALDH enzymatic activity in liver cell lines found ALDH to be positively correlated with CD133 expression. Dual-color flow cytometry analysis found the majority of ALDH+ to be CD133+, yet not all CD133+ HCC cells were ALDH+. Subsequent studies on purified subpopulations found CD133+ALDH+ cells to be significantly more tumorigenic than their CD133−ALDH+ or CD133−ALDH− counterparts, both in vitro and in vivo. These data, combined with those from our previous work, reveal the existence of a hierarchical organization in HCC bearing tumorigenic potential in the order of CD133+ALDH+ > CD133+ALDH− > CD133−ALDH−. ALDH, expressed along CD133, can more specifically characterize the tumorigenic liver CSC population. (Mol Cancer Res 2008;6(7):1146–53)